Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03406780
Other study ID # CAP-1002-DMD-02
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 4, 2018
Est. completion date March 10, 2020

Study information

Verified date June 2020
Source Capricor Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.


Description:

- Approximately 84 eligible study participants will be randomized to either CAP-1002 or placebo in a 1:1 ratio.

- The trial will include visits at Screening, Baseline/Day 1, Week 4, and Months 3, 6, 9, and 12 with IV infusions of CAP-1002 or placebo on Day 1 and Months 3, 6, and 9.

- Safety evaluations will include adverse events, concomitant medications, physical exam, vital signs, 12-lead ECG, and clinical laboratory testing.

- Efficacy will be evaluated in the Performance of the Upper Limb, pulmonary function testing, North Star Ambulatory Assessment (ambulatory subjects only), strength testing, cardiac MRI, and quality of life.

- If trial data suggests an appropriate risk/benefit profile of CAP-1002, Capricor, upon the recommendation of the Data Safety Monitoring Board (DSMB), will introduce an open-label extension study to offer CAP-1002 to study participants who were randomized to placebo and completed all trial visits during the 12-month period.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date March 10, 2020
Est. primary completion date March 10, 2020
Accepts healthy volunteers No
Gender Male
Age group 10 Years and older
Eligibility Inclusion Criteria:

1. Genetically confirmed DMD

2. Reduced upper arm strength as measured by the Performance of Upper Limb

3. Reduced ability to walk/run (if ambulatory)

4. Treatment with systemic glucocorticoids for at least 12 months and at a stable dose at least 6 months prior to study participation, except for weight-based or toxicity-related adjustments

5. Current and up-to-date immunizations

Exclusion Criteria:

1. Left ventricular ejection fraction < 35%

2. BMI > 45

3. Ambulant if = 18 years of age

4. Exon 44 skip-amenable mutation(s) in the DMD gene

5. Deletion mutation(s) encompassing exons 3-7 of the DMD gene

6. Percent-predicted forced vital capacity (FVC) < 35%

7. Chronic respiratory disease not related to DMD (for example, asthma, bronchitis, and tuberculosis)

8. History of diabetes requiring treatment with metformin or insulin within 3 months prior to randomization

9. Treatment with an FDA-approved exon skipping therapy for the treatment of DMD if on a stable dose for less than 24 months prior to randomization

10. Treatment with human growth hormone (HGH) within 3 months prior to randomization, unless on a stable dose for at least 24 months prior to randomization

11. Treatment with idebenone within 3 months prior to randomization

12. Treatment with a cell therapy product within 12 months prior to randomization

13. Treatment with an investigational product within 6 months prior to randomization

Study Design


Intervention

Biological:
CAP-1002
The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
Drug:
Placebo
Placebo

Locations

Country Name City State
United States Children's Hospital Colorado Aurora Colorado
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Children's Hospital Wisconsin Milwaukee Wisconsin
United States Nemours Children's Hospital Orlando Florida
United States University of California, Davis Sacramento California
United States Washington University Saint Louis Missouri
United States University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Capricor Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the mid-level (elbow) dimension of the Performance of the Upper Limb (PUL) The PUL includes functional tasks that relate to activities of daily living that are very important for quality of life. The PUL has been validated for the assessment of upper limb motor function in individuals with DMD. Month 12
Secondary Change in the mid-level (elbow) dimension of the PUL The PUL includes functional tasks that relate to activities of daily living that are very important for quality of life. The PUL has been validated for the assessment of upper limb motor function in individuals with DMD. Months 3, 6, and 9
Secondary Change in regional systolic left ventricular wall thickening as assessed by cardiac MRI Systolic thickening is thought to be a principal mechanism of cardiac output generation in people with DMD. Months 6 and 12
See also
  Status Clinical Trial Phase
Completed NCT05086809 - Investigation of an Updated Bone-anchored Sound Processor N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Recruiting NCT03222375 - SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01922258 - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A
Completed NCT03336645 - Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan Phase 3
Completed NCT04283253 - Predictors of Response in Chronic Stroke N/A
Not yet recruiting NCT06048523 - Prospective Cohort Study of Neurogenetic Diseases N/A
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Active, not recruiting NCT02284126 - Topical Vancomycin for Neurosurgery Wound Prophylaxis Phase 3
Completed NCT05815836 - Precision Medicine in Stroke
Completed NCT00739518 - Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams N/A
Recruiting NCT03678194 - Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application N/A
Recruiting NCT04698421 - Collection of Biological Samples From Patients With Rare Neurological Diseases

External Links